doi: 10.3389/fchem.2025.1536858 Received 29 November 2024 Accepted 27 January 2025 Published 19 March 2025 Volume 13 - 2025 Edited by Federica Aureli, National Institute of Health (ISS), Italy Reviewed by Eric Deconinck, Sciensano (Belgium), Belgium Maria Cristina Gaudiano, National Institute of Health (ISS), Italy Updates Copyright 2025 Blazewicz, Poplawska, Daniszewska, Piorunska and Karynski
They discovered that semaglutide treatment improved body composition by reducing excess body fat, notably abdominal fat, and increasing the proportion of lean body mass, or weight that is not body fat
Further, scientists have explored DSIP applications relating to its abilities to [3]: influence hormones protect against stress reduce pain improve withdrawal management While more research is needed to understand the mechanisms and potential benefits of DSIP, it has piqued the interest of researchers looking to effect better sleep quality and lower stress
Drugs@FDA, NDA 022505 (approved 10 Nov 2010)